Q3 FY2026 · ended Sep 30, 2026 · Revenue $7.16M, -48.0% YoY · Filed Nov 5, 2026
Intellia Therapeutics, Inc. (NTLA) files with the SEC under industry code 2835, In Vitro & In Vivo Diagnostic Substances. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $7.2 million and a net loss of $127.5 million. Free cash flow was -$86.3 million. As of Sep 30, 2026 it held $614.8 million in cash and investments and $230.1 million in total debt.
Revenue
$7.16M
-48.0% vs year-ago quarter
Net income
$-127.48M
-25.8% vs year-ago quarter
Operating cash flow
$-85.43M
-11.1% vs year-ago quarter
Free cash flow
$-86.32M
-12.2% vs year-ago quarter
EPS
$-0.91
+1.1% vs year-ago quarter
Dividend per share
None
Shares outstanding
140.36M
+21.2% vs year-ago quarter
Net cash
$384.66M
Q3 FY2026
Operating margin
-821.2%
TTM
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- NTLA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1652130
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
- Alpha Teknova, Inc. TKNO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $7.2M | $7.7M | $15.0M | $23.0M | $13.8M |
| Operating income | -$122.3M | -$112.8M | -$100.5M | -$98.7M | -$111.5M |
| Net income | -$127.5M | -$106.6M | -$96.2M | -$95.8M | -$101.3M |
| Diluted EPS | -$0.91 | -$0.80 | -$0.81 | -$0.83 | -$0.92 |
| Operating cash flow | -$85.4M | -$83.1M | -$117.3M | -$69.3M | -$76.9M |
| Free cash flow | -$86.3M | -$84.9M | -$117.4M | -$69.4M | -$76.9M |
| Total assets | $902.6M | $857.2M | $758.8M | $842.1M | $925.3M |
| Total liabilities | $289.5M | $129.5M | $137.8M | $170.7M | $176.9M |
| Stockholders' equity | $613.1M | $727.7M | $620.9M | $671.4M | $748.4M |
| Cash and investments | $614.8M | $628.4M | $517.2M | $605.1M | $669.9M |
| Total debt | $230.1M | $73.4M | $80.5M | $93.3M | $98.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 8, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Material agreement, New debt, Regulation FD disclosure
|
Sep 4, 2026 | Sep 4, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 15, 2026 | Jun 13, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 10, 2026 | Jun 9, 2026 |
All 721 Intellia Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.